Long-term protection in children with meningococcal C conjugate vaccination: lessons learned

References

• World Health Organization.Wkly Epidemiol. Rec.37, 281–288 (2001).
   Google Scholar
• Taha MK, Parent du Chatelet IP, Schlumberger M et al.Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J. Clin. Microbiol.40, 1083–1084 (2002).
   PubMed Web of Science ®Google Scholar
• Ouedraogo-Traore R, Hoiby EA, Sanou I et al. Molecular characteristics of Neisseria meningitidis strains isolated in Burkina Faso in 2001. Scan. J. Infect. Dis.34, 804–807 (2002).
   PubMedGoogle Scholar
• Offit PA, Peter G. The meningococcal vaccine – public policy and individual choices. N. Engl. J. Med.349, 2353–2356 (2003).
   PubMed Web of Science ®Google Scholar
• Baker MG, Martin D R, Kieft C, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000. J. Paediatr. Child Health.37, S13–S19 (2001).
   Google Scholar
• Dyet KH, Martin DR. Clonal analysis of the serogroup B meningococci causing New Zealand’s epidemic. Epidemiol. Infect.134, 377–383 (2006).
   PubMed Web of Science ®Google Scholar
• Sacchi CT, Pessoa LL, Ramos SR et al. Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex. J. Clin. Microbiol.30, 1734–1738 (1992).
   PubMed Web of Science ®Google Scholar
• Bovre K, Gedde-Dahl TW. Epidemiological patterns of meningococcal disease in Norway 1975–1979. NIPH Ann.3, 9–22 (1980).
   Google Scholar
• Cruz C, Pavez G, Aguilar E et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol. Infect.105, 119–126 (1990).
   PubMed Web of Science ®Google Scholar
• Sierra GVG, Campa HC, Varcacel NW et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann14, 195–207 (1991).
   PubMedGoogle Scholar
• Artenstein MS, Schneider H, Tingley MD. Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964–1970. Bull. World Health Organ.45, 275–278 (1971).
   Google Scholar
• Souza de Morais J, Munford RS, Risi JB et al. Epidemic disease due to serogroup C Neisseria meningitidis in Sao Paulo, Brazil.J. Infect. Dis.129, 568–571 (1974).
   PubMed Web of Science ®Google Scholar
• Wang JF, Caugant DA, Morelli G et al. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis.J. Infect. Dis.167, 1320–1329 (1993).
   PubMed Web of Science ®Google Scholar
• Berron S, De La Fuente L, Martin E et al. Increasing incidence of meningococcal disease in Spain associated with a new variant of serogroup C. Eur. J. Clin. Microbiol. Infect. Dis.17, 85–89 (1998).
   PubMed Web of Science ®Google Scholar
• Ramsay M, Kaczmarski E, Rush M et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun. Dis. Rep. Rev.7, R49–R54 (1997).
   PubMedGoogle Scholar
• Krizova P, Musilek M. Changing epidemiology of meningococcal invasive disease in the Czech Republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37. Cent. Eur. J. Public Health3, 189–194 (1995).
   PubMedGoogle Scholar
• Ashton FE, Ryan JA, Borczyk A et al. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J. Clin. Microbiol.29, 2489–2493 (1991).
   PubMed Web of Science ®Google Scholar
• Whalen CM, Hockin JC, Ryan A et al. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992: emergence of a virulent clone of Neisseria meningitidis. JAMA273, 390–394 (1995).
   PubMed Web of Science ®Google Scholar
• Gray SJ, Trotter CL, Ramsay ME et al. Epidemiology of meningococcal disease in England and Wales 1993/4 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol.55, 887–896 (2006).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20, (Suppl. 1), S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Miller E et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.J. Infect. Dis.179, 1569–1572 (1999).
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Findlow J et al. Evaluation of De-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming and bactericidal activity against O-acetylated and De-acetylated serogroup C strains. Infect. Immun.69, 2378–2382 (2001).
   PubMed Web of Science ®Google Scholar
• MacLennan JM, Shackley F, Heath PT et al. Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA283, 2795–2801 (2000).
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Goldblatt D et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.J. Infect. Dis.183, 160–163 (2001).
   PubMed Web of Science ®Google Scholar
• Richmond P, Kaczmarski E, Borrow R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.J. Infect. Dis.181, 761–764 (2000).
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies. J. Exp. Med.129, 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: II. Development of natural immunity. J. Exp. Med.129, 1327–1348 (1969).
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Requirements for meningococcal polysaccharide vaccine. World Health Organization technical report series, no. 594. World Health Organization, Geneva, Switzerland (1976).
   Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England. Clin. Diag. Lab. Immunol.10, 780–786 (2003).
   PubMedGoogle Scholar
• Borrow R, Miller E. Surrogates of protection. In: Handbook of meningococcal disease. Frosch M, Maiden M (Eds). Wiley-CH. 323–351 (2006).
   Google Scholar
• Borrow R, Goldblatt D, Finn A et al. Immunogenicity of and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect. Immun.71, 5549–5555 (2003).
   PubMed Web of Science ®Google Scholar
• Vu DM, Kelly D, Heath PT et al. Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization.J. Infect. Dis.194, 231–237 (2006).
   PubMed Web of Science ®Google Scholar
• Borrow R R, Goldblatt D andrews N et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J. Infect. Dis.186, 1353–1357 (2002).
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Green B et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr. Infect. Dis. J.24, 128–131 (2005).
   PubMed Web of Science ®Google Scholar
• McVernon J, MacLennan J, Buttery J et al. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr. Infect. Dis. J.21, 747–753 (2002).
   PubMed Web of Science ®Google Scholar
• Choo S, Zuckerman J, Goilav C et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine18, 2686–2692 (2000).
   PubMed Web of Science ®Google Scholar
• Borrow R andrews N, Goldblatt D et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection. Infect. Immun.69, 1568–1573 (2001).
   PubMed Web of Science ®Google Scholar
• Leach A, Twumasi PA, Kumah S et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis.175, 200–204 (1997).
   PubMed Web of Science ®Google Scholar
• Macdonald NE, Halperin SA, Law BJ et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers. JAMA280, 1685–1689 (1998).
   PubMed Web of Science ®Google Scholar
• Vu DM, de Boer AW, Danzig L et al. Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin. Vaccine Immunol.13, 605–610 (2006).
   PubMedGoogle Scholar
• Goldblatt D, Borrow R, Miller E. Natural and vaccine induced immunity and immunological memory to Neisseria meningitidis serogroup C in young adults.J. Infect. Dis.185, 397–400 (2002).
   PubMed Web of Science ®Google Scholar
• Richmond P, Goldblatt D, Fusco PC et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine18, 641–646 (1999).
   PubMed Web of Science ®Google Scholar
• Campagne G, Garba A, Fabre P et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J.19, 144–150 (2000).
   PubMed Web of Science ®Google Scholar
• Ahman H, Kayhty H, Vuorela A et al. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine17, 2726–2732 (1999).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Voloshen T, Passador S. Kinetics of booster responses to Haemophilus influenzae type B conjugate after combined diphtheria-tetanus-acelluar pertussis-Haemophilus influenzae type b vaccination in infants. Pediatr. Infect. Dis. J.18, 1106–1108 (1999).
   PubMed Web of Science ®Google Scholar
• Nurkka A, Joensuu J, Henckaerts I et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr. Infect. Dis. J.23, 1008–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Tsai TF, Borrow R, Gnehm HE et al. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection? Clin. Vacc. Immunol.13, 854–861 (2006).
   PubMedGoogle Scholar
• Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet359, 1829–1831 (2002).
   PubMed Web of Science ®Google Scholar
• Ramsay ME andrews NJ, Trotter CL. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br. Med. J.326, 365–366 (2003).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet354, 615–616 (1999).
   PubMed Web of Science ®Google Scholar
• Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol.51, 717–722 (2002).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease and the impact of serogroup C conjugate vaccination. Am. J. Epidemiol.162, 89–100 (2005).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Edmunds WJ, Ramsay ME et al. Modelling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Human Vaccines2, 68–73 (2006).
   PubMed Web of Science ®Google Scholar
• Ramsay ME andrews N, Kaczmarski EB et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet357, 195–196 (2001).
   PubMed Web of Science ®Google Scholar
• Trotter CL andrews NJ, Kaczmarski EB et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364, 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, Garcia M et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine23, 4097–4100 (2005).
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the UK.J. Infect. Dis.194, 1745–1752 (2006).
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr. Infect. Dis. J.25, 79–80 (2006).
   PubMed Web of Science ®Google Scholar
• Edwards EA, Devine LF, Sengbusch GH et al. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand. J. Infect. Dis.9, 105–110 (1977).
   PubMed Web of Science ®Google Scholar
• Boutet R, Stuart JM, Kaczmarski EB et al. Risk of laboratory-acquired meningococcal disease. J. Hosp. Infect.49, 282–284 (2001).
   PubMed Web of Science ®Google Scholar
• Lambert P-H, Liu M, Siegrist C-A. Can successful vaccines teach us how to induce efficient protective immune responses? Nat. Med.11(Suppl.), 554–559 (2005).
   Google Scholar
• Lucas AH, Granoff DM. Imperfect memory and the development of Haemophilus influenzae type B disease. Pediatr. Infect. Dis. J.20, 235–239 (2001).
   PubMed Web of Science ®Google Scholar
• Ramsay ME, McVernon J andrews NJ et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method.J. Infect. Dis.188, 481–485 (2003).
   PubMed Web of Science ®Google Scholar
• Ramsay M, Miller E andrews N et al. Epidemiological data are essential (rapid response to H. Peltola, E. Salo and H. Saxen. Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data). Br. Med. J.330, 18–19 (2005).
   PubMedGoogle Scholar
• Goldblatt D, Vas AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization.J. Infect. Dis.177, 1112–1115 (1998).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Richmond P, Millard E et al.The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis containing diphtheria, tetanus and pertussis vaccine combination.J. Infect. Dis.180, 538–541 (1999).
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Canny M, O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill.10, E050929.2. (2005).
   Google Scholar
• De Wals P, Trottier P, Pepin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine24, 3500–3504 (2006).
   PubMed Web of Science ®Google Scholar